Lewis Mervin

1.6k total citations · 1 hit paper
32 papers, 736 citations indexed

About

Lewis Mervin is a scholar working on Computational Theory and Mathematics, Molecular Biology and Materials Chemistry. According to data from OpenAlex, Lewis Mervin has authored 32 papers receiving a total of 736 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Computational Theory and Mathematics, 19 papers in Molecular Biology and 9 papers in Materials Chemistry. Recurrent topics in Lewis Mervin's work include Computational Drug Discovery Methods (23 papers), Machine Learning in Materials Science (9 papers) and Microbial Natural Products and Biosynthesis (3 papers). Lewis Mervin is often cited by papers focused on Computational Drug Discovery Methods (23 papers), Machine Learning in Materials Science (9 papers) and Microbial Natural Products and Biosynthesis (3 papers). Lewis Mervin collaborates with scholars based in United Kingdom, Sweden and Singapore. Lewis Mervin's co-authors include Ola Engkvist, Andreas Bender, Avid M. Afzal, Jon Paul Janet, Alexey Voronov, Hannes H. Loeffler, Richard P. Lewis, Alessandro Tibo, Jiazhen He and Ian P. Barrett and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Bioinformatics.

In The Last Decade

Lewis Mervin

31 papers receiving 720 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reinvent 4: Modern AI–driven generative molecule design

2024 104 citations Hannes H. Loeffler, Jiazhen He et al. Journal of Cheminformatics profile →

Peers

Countries citing papers authored by Lewis Mervin

Since Specialization

Citations

This map shows the geographic impact of Lewis Mervin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lewis Mervin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lewis Mervin more than expected).

Fields of papers citing papers by Lewis Mervin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lewis Mervin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lewis Mervin. The network helps show where Lewis Mervin may publish in the future.

Co-authorship network of co-authors of Lewis Mervin

This figure shows the co-authorship network connecting the top 25 collaborators of Lewis Mervin. A scholar is included among the top collaborators of Lewis Mervin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lewis Mervin. Lewis Mervin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Temporal distribution shift in real-world pharmaceutical data: Implications for uncertainty quantification in QSAR models 2025 ·Lirias (KU Leuven) ·(unknown), (unknown), Susanne Winiwarter, Lewis Mervin, Ádám Arany, Ola Engkvist	0
2	Enhancing uncertainty quantification in drug discovery with censored regression labels 2025 ·Lirias (KU Leuven) ·(unknown), (unknown), Susanne Winiwarter, Lewis Mervin, Ádám Arany, Ola Engkvist	3
3	Achieving well-informed decision-making in drug discovery: a comprehensive calibration study using neural network-based structure-activity models 2025 ·Journal of Cheminformatics ·(unknown), Ola Engkvist, Lewis Mervin, Yves Moreau, Ádám Arany	1
4	QSARtuna: An Automated QSAR Modeling Platform for Molecular Property Prediction in Drug Design 2024 ·Journal of Chemical Information and Modeling ·Lewis Mervin, Alexey Voronov, Mikhail Kabeshov, Ola Engkvist	10
5	Reinvent 4: Modern AI–driven generative molecule design breakdown → 2024 ·Journal of Cheminformatics ·Hannes H. Loeffler, Jiazhen He, Alessandro Tibo, Jon Paul Janet, Alexey Voronov, Lewis Mervin, Ola Engkvist	104
6	Data‐driven approaches for identifying hyperparameters in multi‐step retrosynthesis 2023 ·Molecular Informatics ·Annie M. Westerlund, (unknown), Lewis Mervin, Samuel Genheden	7
7	In silico prediction and biological assessment of novel angiogenesis modulators from traditional Chinese medicine 2023 ·Frontiers in Pharmacology ·Yingli Zhu, Hongbin Yang, Liwen Han, Lewis Mervin, (unknown), Peihai Li, (unknown), Maria‐Anna Trapotsi, Kechun Liu, (unknown), Andreas Bender	4
8	Artificial intelligence in molecular de novo design: Integration with experiment 2023 ·Current Opinion in Structural Biology ·Jon Paul Janet, Lewis Mervin, Ola Engkvist	15
9	Cell Morphological Profiling Enables High-Throughput Screening for PROteolysis TArgeting Chimera (PROTAC) Phenotypic Signature 2022 ·ACS Chemical Biology ·Maria‐Anna Trapotsi, Elizabeth Mouchet, Guy Williams, Tiziana Monteverde, (unknown), Riku Turkki, Filip Miljković, (unknown), Lewis Mervin, Kenneth R. Pryde, Erik Müllers, Ian P. Barrett, Ola Engkvist, Andreas Bender, Kévin Moreau	25
10	AI for drug design: From explicit rules to deep learning 2022 ·SHILAP Revista de lepidopterología ·Lewis Mervin, Samuel Genheden, Ola Engkvist	7
11	Towards understanding antimicrobial activity, cytotoxicity and the mode of action of dichapetalins A and M using in silico and in vitro studies 2021 ·Toxicon ·(unknown), Dezső Módos, Lewis Mervin, (unknown), (unknown), Beverly Egyir, Lily Paemka, (unknown), (unknown), Avid M. Afzal, Andreas Bender	6
12	Leveraging heterogeneous data from GHS toxicity annotations, molecular and protein target descriptors and Tox21 assay readouts to predict and rationalise acute toxicity 2019 ·Journal of Cheminformatics ·Chad H. G. Allen, Lewis Mervin, (unknown), Andreas Bender	8
13	Extending in Silico Protein Target Prediction Models to Include Functional Effects 2018 ·Frontiers in Pharmacology ·Lewis Mervin, Avid M. Afzal, Lars Brive, Ola Engkvist, Andreas Bender	7
14	Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs 2018 ·Nature Communications ·Hamid R. Noori, Lewis Mervin, Vahid Bokharaie, (unknown), (unknown), Stefan Fritze, (unknown), (unknown), (unknown), (unknown), Nikos K. Logothetis, Andreas Bender, Rainer Spanagel	12
15	Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases 2017 ·Journal of Cheminformatics ·(unknown), (unknown), Jhonny Azuaje, Marı́a Isabel Loza, Fredrik Svensson, Azedine Zoufir, Lewis Mervin, Graham Ladds, José Brea, Robert C. Glen, Eddy Sotelo, Andreas Bender	12
16	Novel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer 2016 ·ACS Omega ·(unknown), Vijay Pandey, Chakrabhavi Dhananjaya Mohan, (unknown), Shobith Rangappa, (unknown), (unknown), Shardul Paricharak, Lewis Mervin, Krishna C. Bulusu, (unknown), Andreas Bender, Shuhei Yamada, Basappa Basappa, Peter E. Lobie, Kanchugarakoppal S. Rangappa	45
17	Current Trends in Drug Sensitivity Prediction 2016 ·Current Pharmaceutical Design ·Isidro Cortés‐Ciriano, Lewis Mervin, Andreas Bender	15
18	Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway 2016 ·PLoS ONE ·Chakrabhavi Dhananjaya Mohan, (unknown), Shobith Rangappa, Lewis Mervin, Surender Mohan, Shardul Paricharak, Sefer Baday, Feng Li, Muthu K. Shanmugam, Arunachalam Chinnathambi, Mohamed E. Zayed, Sulaiman Ali Alharbi, Andreas Bender, Gautam Sethi, Basappa Basappa, Kanchugarakoppal S. Rangappa	115
19	A Nano-MgO and Ionic Liquid-Catalyzed ‘Green’ Synthesis Protocol for the Development of Adamantyl-Imidazolo-Thiadiazoles as Anti-Tuberculosis Agents Targeting Sterol 14α-Demethylase (CYP51) 2015 ·PLoS ONE ·(unknown), (unknown), Chakrabhavi Dhananjaya Mohan, (unknown), Shobith Rangappa, Surender Mohan, Manasa Chandramouli, Shardul Paricharak, Lewis Mervin, Julian E. Fuchs, (unknown), Andreas Bender, Basappa Basappa, Kanchugarakoppal S. Rangappa	19
20	Target prediction utilising negative bioactivity data covering large chemical space 2015 ·Journal of Cheminformatics ·Lewis Mervin, Avid M. Afzal, (unknown), Richard P. Lewis, Ola Engkvist, Andreas Bender	91

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact